Antigen-presenting liposomes are effective in treatment of recurrent herpes simplex virus genitalis in guinea pigs.
The therapeutic and immunologic effects of a liposome preparation containing both a macrophage activator, muramyl-tripeptide-phosphatidylethanolamine, and a recombinant antigen, glycoprotein D of herpes simplex virus type 1, have been investigated. This preparation was tested in vitro for the ability to stimulate peripheral blood lymphocytes and in vivo for the control of recurrent herpes genitalis in guinea pigs. Our results show that the liposome-antigen-adjuvant preparation is capable of enhancing antigen-specific lymphocyte stimulation, which may be related to the observed 75% suppression of the frequency and severity of reactivation of recurrent herpes simplex virus type 2 genitalis compared with that of placebo controls.
Ho
R J
RJ
Department of Medicine, Stanford University School of Medicine, California 94305.
Burke
R L
RL
Merigan
T C
TC
D000119:Acetylmuramyl-Alanyl-Isoglutamine / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000627:therapeutic use; D000818:Animals; D000956:Antigens, Viral / Q000008:administration & dosage*; D000998:Antiviral Agents / Q000008:administration & dosage*; D005260:Female; D006168:Guinea Pigs; D006558:Herpes Genitalis / Q000628:therapy*; D007167:Immunotherapy; D008081:Liposomes; D010713:Phosphatidylcholines; D010714:Phosphatidylethanolamines / Q000008:administration & dosage* / Q000627:therapeutic use; D011994:Recombinant Proteins / Q000008:administration & dosage; D018139:Simplexvirus / Q000276:immunology*; D014759:Viral Envelope Proteins / Q000008:administration & dosage*
D000956:Antigens, Viral; D000998:Antiviral Agents; D008081:Liposomes; D010713:Phosphatidylcholines; D010714:Phosphatidylethanolamines; D011994:Recombinant Proteins; D014759:Viral Envelope Proteins; C039447:glycoprotein D, Human herpesvirus 1; C037144:mifamurtide; D000119:Acetylmuramyl-Alanyl-Isoglutamine; C017251:1,2-oleoylphosphatidylcholine